This HTML5 document contains 61 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n7http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n18http://linked.opendata.cz/resource/drugbank/drug/DB06810/identifier/chebi/
n4http://www.rxlist.com/
n13http://bio2rdf.org/drugbank:
n20http://linked.opendata.cz/resource/drugbank/drug/DB06810/identifier/wikipedia/
n19http://linked.opendata.cz/resource/drugbank/drug/DB06810/identifier/pharmgkb/
admshttp://www.w3.org/ns/adms#
n8http://www.drugs.com/mtm/
n16http://linked.opendata.cz/resource/drugbank/drug/DB06810/identifier/kegg-compound/
n22http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n6http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n5http://linked.opendata.cz/ontology/drugbank/
n17http://linked.opendata.cz/resource/drugbank/drug/DB06810/identifier/kegg-drug/
n21http://linked.opendata.cz/resource/drugbank/drug/DB06810/identifier/drugbank/
n9http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n11http://linked.opendata.cz/resource/atc/
n10http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB06810
rdf:type
n5:Drug
n5:description
Plicamycin is an antineoplastic antibiotic produced by Streptomyces plicatus. It has been used in the treatment of testicular cancer, Paget's disease of bone, and, rarely, the management of hypercalcemia. The manufacturer discontinued plicamycin in 2000.
n5:generalReferences
# Wohlert SE, Kunzel E, Machinek R, Mendez C, Salas JA, Rohr J: The structure of mithramycin reinvestigated. J Nat Prod. 1999 Jan;62(1):119-21. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/9917296
n5:group
approved withdrawn
n5:indication
For the treatment of testicular cancer, as well as hypercalcemia and hypercalciuria associated with a variety of advanced forms of cancer.
owl:sameAs
n13:DB06810 n22:DB06810
dcterms:title
Plicamycin
adms:identifier
n16:C12389 n17:D00468 n18:31856 n19:PA165958411 n20:Plicamycin n21:DB06810
n5:mechanismOfAction
Plicamycin is presumed to inhibit cellular and enzymic RNA synthesis by forming a complex with DNA. Plicamycin may also lower calcium serum levels by inhibiting the effect of parathyroid hormone upon osteoclasts or by blocking the hypercalcemic action of pharmacologic doses of vitamin D.
n5:routeOfElimination
Radioautography studies with 3H-labeled plicamycin in mice show that the greatest concentrations of the isotope are in the Kupffer cells of the liver and cells of the renal tubules. Plicamycin is rapidly cleared from the blood within the first 2 hours and excretion is also rapid. 67% percent of measured excretion occurs within 4 hours, 75% within 8 hours, and 90% is recovered in the first 24 hours after injection.
n5:synonym
Mithramycin Mithramycine Mithramycinum Plicamycin Plicamycine Aureolic acid Plicamycinum Mithracin
n5:toxicity
The most important form of toxicity associated with the use of plicamycin consists of a dose-related bleeding syndrome which usually begins with an episode of epistaxis. Plicamycin crosses the blood-brain barrier; the concentration found in brain tissue is low but it persists longer than in other tissues.
n5:proteinBinding
There is no evidence of protein binding, nor is there any evidence of metabolism of the carbohydrate moiety of the drug to carbon dioxide and water with loss through respiration.
n5:synthesisReference
Jurgen Rohr, Lily Remsing, Mohammad Nur-e-Alam, Jose Salas, Carmen Mendez, Alfredo Brana, Ana Gonzalez, "Derivatives of mithramycin and methods of making and uses thereof." U.S. Patent US20050192432, issued September 01, 2005.
n6:hasConcept
n7:M0013935
foaf:page
n4:mithracin-drug.htm n8:plicamycin.html
n5:IUPAC-Name
n9:271B5533-363D-11E5-9242-09173F13E4C5
n5:InChI
n9:271B5539-363D-11E5-9242-09173F13E4C5
n5:Molecular-Formula
n9:271B5538-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight
n9:271B5535-363D-11E5-9242-09173F13E4C5
n5:Monoisotopic-Weight
n9:271B5536-363D-11E5-9242-09173F13E4C5
n5:SMILES
n9:271B5537-363D-11E5-9242-09173F13E4C5
n5:Water-Solubility
n9:271B5531-363D-11E5-9242-09173F13E4C5
n5:logP
n9:271B5532-363D-11E5-9242-09173F13E4C5 n9:271B552F-363D-11E5-9242-09173F13E4C5
n5:logS
n9:271B5530-363D-11E5-9242-09173F13E4C5
n10:hasATCCode
n11:L01DC02
n5:H-Bond-Acceptor-Count
n9:271B553F-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Donor-Count
n9:271B5540-363D-11E5-9242-09173F13E4C5
n5:InChIKey
n9:271B553A-363D-11E5-9242-09173F13E4C5
n5:Polar-Surface-Area--PSA-
n9:271B553B-363D-11E5-9242-09173F13E4C5
n5:Polarizability
n9:271B553D-363D-11E5-9242-09173F13E4C5
n5:Refractivity
n9:271B553C-363D-11E5-9242-09173F13E4C5
n5:Rotatable-Bond-Count
n9:271B553E-363D-11E5-9242-09173F13E4C5
n5:casRegistryNumber
18378-89-7
n5:category
n5:Bioavailability
n9:271B5545-363D-11E5-9242-09173F13E4C5
n5:Ghose-Filter
n9:271B5547-363D-11E5-9242-09173F13E4C5
n5:MDDR-Like-Rule
n9:271B5548-363D-11E5-9242-09173F13E4C5
n5:Melting-Point
n9:271B5549-363D-11E5-9242-09173F13E4C5
n5:Number-of-Rings
n9:271B5544-363D-11E5-9242-09173F13E4C5
n5:Physiological-Charge
n9:271B5543-363D-11E5-9242-09173F13E4C5
n5:Rule-of-Five
n9:271B5546-363D-11E5-9242-09173F13E4C5
n5:Traditional-IUPAC-Name
n9:271B5534-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-acidic-
n9:271B5541-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-basic-
n9:271B5542-363D-11E5-9242-09173F13E4C5